Talphera, Inc. (TLPH) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Talphera, Inc. (TLPH) Healthcare & Pipeline Overview

Talphera, Inc. (TLPH) is a specialty pharmaceutical company focused on developing and commercializing therapies for medically supervised settings, with a primary focus on Niyad, a nafamostat formulation being investigated as an anticoagulant. The company operates within the niche market of therapies for medically supervised environments.

What Is the Investment Thesis for TLPH?

Talphera, Inc. (TLPH) presents a high-risk, high-reward investment opportunity centered on its pipeline of specialized pharmaceutical products. The primary value driver is the successful development and commercialization of Niyad, its lead product candidate, targeting anticoagulation in extracorporeal circuits. Positive clinical trial results and subsequent regulatory approval for Niyad could significantly boost the company's market capitalization. The development of LTX-608, with its potential applications in treating conditions like COVID-19 and ARDS, represents another growth catalyst. However, the company's negative profit margin of -51035.7% and gross margin of -4075.0% highlight significant financial challenges. Investors should carefully consider the risks associated with pharmaceutical development, regulatory hurdles, and the company's current financial position before investing. The company's small market cap of $61.8M also indicates higher volatility.

Based on FMP financials and quantitative analysis

TLPH Key Highlights

Market Cap of $61.8M indicates a micro-cap company with potential for high growth but also significant risk.

• Profit Margin of -51035.7% reflects substantial losses and the need for successful product commercialization to achieve profitability.
• Gross Margin of -4075.0% indicates that the cost of goods sold significantly exceeds revenue, highlighting operational inefficiencies.
• Beta of 0.56 suggests lower volatility compared to the overall market.
• Focus on therapies for medically supervised settings provides a niche market with specific needs and potential for targeted product development.

Who Are TLPH's Competitors?

TLPH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TLPH's Key Strengths?

Focus on therapies for medically supervised settings.

• Lead product candidate Niyad targeting a specific need.
• Pipeline of products addressing multiple conditions.
• Experienced management team.

What Are TLPH's Weaknesses?

Significant losses and negative profit margin.

• Small market capitalization.
• Dependence on successful product development and commercialization.
• Limited financial resources.

What Could Drive TLPH Stock Higher?

Clinical trial results for Niyad as an anticoagulant.

• Regulatory approval decisions for Niyad.
• Clinical trial progress for LTX-608 in treating COVID-19 and ARDS.
• Commercialization of Fedsyra and PFS-02 syringes.

What Are the Key Risks for TLPH?

Financial-distress signal — its Altman Z-Score of -23.07 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-87.3%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Regulatory delays or rejection of product approvals.
• Clinical trial failures for Niyad or LTX-608.
• Competition from established pharmaceutical companies.
• Financial losses and need for additional funding.
• Product liability claims.

What Are the Growth Opportunities for TLPH?

• Niyad Commercialization: The successful completion of clinical trials and subsequent commercialization of Niyad as an anticoagulant for extracorporeal circuits represents a significant growth opportunity. The market for anticoagulants is substantial, and a novel formulation like Niyad could capture a significant share, potentially generating substantial revenue within the next 2-3 years pending regulatory approvals. The market size for anticoagulants is estimated to be in the billions of dollars globally.
• LTX-608 Expansion: The development of LTX-608 as an anti-inflammatory and antiviral treatment offers a broad range of potential applications, including COVID-19, DIC, ARDS, and acute pancreatitis. Successful clinical trials and regulatory approval could open up significant market opportunities, particularly in addressing unmet needs in critical care settings. The timeline for this growth opportunity is dependent on clinical trial progress, with potential revenue generation within 3-5 years.
• Fedsyra and PFS-02 Syringes: The commercialization of Fedsyra (pre-filled ephedrine syringe) and PFS-02 (pre-filled phenylephrine syringe) offers a focused growth opportunity within the emergency medicine market. These pre-filled syringes provide ease of use and rapid administration, potentially capturing a share of the market for emergency medications. Revenue generation from these products could begin within the next 1-2 years following regulatory approvals and market launch.
• Strategic Partnerships: Forming strategic partnerships with larger pharmaceutical companies or healthcare providers could accelerate the development and commercialization of Talphera's product pipeline. These partnerships could provide access to funding, expertise, and distribution channels, enhancing the company's growth prospects. The timeline for securing partnerships is variable, but potential benefits could be realized within the next 1-3 years.
• Geographic Expansion: Expanding into new geographic markets, particularly in Europe and Asia, could drive revenue growth for Talphera's products. These markets offer significant opportunities for therapies targeting medically supervised settings. The timeline for geographic expansion is dependent on regulatory approvals and market entry strategies, with potential revenue generation within 3-5 years.

What Are TLPH's Competitive Advantages?

• Specialized product pipeline focused on niche markets.
• Intellectual property protection for novel formulations.
• Regulatory expertise in navigating the pharmaceutical approval process.
• Established relationships with healthcare providers in medically supervised settings.

What Does TLPH Do?

Talphera, Inc., headquartered in San Mateo, California, is a specialty pharmaceutical company dedicated to the development and commercialization of therapies intended for use in medically supervised settings. Founded in 2005, the company was formerly known as AcelRx Pharmaceuticals, Inc. before rebranding to Talphera, Inc. in January 2024. The company's lead product candidate is Niyad, a lyophilized formulation of nafamostat, currently under an investigational device exemption as an anticoagulant for the extracorporeal circuit. This targets a critical need in procedures requiring blood circulation outside the body. Beyond Niyad, Talphera is also developing LTX-608, an anti-inflammatory and antiviral treatment with potential applications across multiple conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. The pipeline also includes Fedsyra, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe, both designed for ease of use and rapid administration in emergency situations. Talphera's strategic focus on niche therapies and medically supervised environments differentiates it within the broader pharmaceutical landscape.

What Products and Services Does TLPH Offer?

• Develop therapies for medically supervised settings.
• Focus on niche pharmaceutical markets.
• Develop Niyad, a lyophilized formulation of nafamostat, as an anticoagulant.
• Develop LTX-608 as an anti-inflammatory and antiviral treatment.
• Develop Fedsyra, a pre-filled ephedrine syringe.
• Develop PFS-02, a pre-filled phenylephrine syringe.

How Does TLPH Make Money?

• Develop and commercialize specialized pharmaceutical products.
• Seek regulatory approvals for their therapies.
• Generate revenue through product sales.
• Potentially establish partnerships for development and distribution.

What Industry Does TLPH Operate In?

Talphera, Inc. operates within the specialty pharmaceutical industry, a segment characterized by its focus on niche markets and specific therapeutic areas. The industry is driven by innovation in drug development and the increasing demand for targeted therapies. Competition is intense, with both large pharmaceutical companies and smaller biotechs vying for market share. Talphera's focus on therapies for medically supervised settings positions it within a specialized segment of this industry. The overall pharmaceutical market is expected to continue growing, driven by an aging population and increasing healthcare spending.

Who Are TLPH's Key Customers?

• Hospitals and medical centers.
• Operating rooms and surgical centers.
• Intensive care units (ICUs).
• Emergency medical services (EMS).

Company Profile

Talphera, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in San Mateo, US. The company is led by CEO Vincent J. Angotti. TLPH has traded publicly since 2011.

How Talphera, Inc. Is Valued

Talphera, Inc. carries a market capitalization of $61.8M, placing it in the micro-cap category. Relative to its peer group, TLPH's quantitative score of 19/100 is below the peer average of 63/100.

Return on equity for Talphera, Inc. stands at -87.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -56.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -19.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.29 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -16.5%, the inverse of the P/E and a quick read on earnings relative to price.

Talphera, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -23.07 places it in the distress zone, a signal of elevated financial risk.

Wall Street analysts project Talphera, Inc. revenue of about $4.0M for fiscal 2026, with EPS near $-0.24.

TLPH Financials

TLPH Latest News

No recent news available for TLPH.

TLPH Analyst Consensus

TLPH MoonshotScore

Common Questions About TLPH (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources